6th Mar 2018 09:20
LONDON (Alliance News) - FTSE 250-listed healthcare investment company Syncona Ltd said on Tuesday its portfolio company Autolus Ltd, has filed a confidential submission of a registration statement to the US Securities & Exchange Commission for an initial public offering in the US.
Autolus is a UK-based biopharmaceutical company which develops T cell therapies for the treatment of cancer. The process is currently at a preliminary stage and the timing and terms of the IPO are subject to market conditions and other factors.
"Syncona is the largest shareholder in Autolus and is highly supportive of the company over the long-term in line with Syncona's strategy to build global leaders in life science and deliver transformational treatments to patients," Syncona said in a statement.
Life sciences company Arix Bioscience PLC also notes the announcement by Autolus for its potential initial public offering.
Shares in Syncona were up 3.5% at 204.25 pence, while Arix Bioscience shares were up 0.7% at 213.00p on Tuesday.
Related Shares:
ARIX.LSyncona
